BOC International is optimistic about Kingsley Biotech's hig...

Moomoo AI Oct 18, 2023 22:19

BOC International is optimistic about Kingsley Biotech's high scarcity, significant synergy between businesses, and the ability to operate and finance independently. BOC International expects high expectations for Cilta-cel's future revenue and continues to be optimistic about Kingsley Biotech's ratings.

BOC International: Reiterates Kingsley Biotech's (01548) “Buy” Rating Target Price of HK$28.43

Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates. Read more

See Original

Report

4310 Views

Comment

Moomoo AI

Moomoo AI Official Account

Your AI assistant for discovering investment opportunities.

4036Followers

0Following

9038Visitors